Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus-Rituximab versus steroids plus cyclophosphamide in primary membranous nephropathy
2013-000226-55Phase 3Active
- Sponsor
- Fundación Renal Española
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in idiopathic membranous glomerulonephritis (IMG) comparing Sequential tacrolimus followed by rituximab with Cyclical corticosteroids plus cyclophosphamide (2 arms). Primary endpoint: Complete or partial remission at 24 months. Started Jun 2013; status: active.
02
Drugs
tacrolimusrituximabcyclophosphamidecorticosteroids
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2013-000226-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000226-55.